title: In Brief: Myeloid-derived suppressor cells in cancer.
abstract: The role of myeloid-derived suppressor cells (MDSCs) in cancer development has become clear over recent years, and MDSC targeting is an emerging opportunity for enhancing the effectiveness of current anticancer therapies. As MDSCs are not only able to limit anti-tumour T-cell responses, but also to promote tumour angiogenesis and invasion, their monitoring has prognostic and predictive value. Herein, we review the key features of MDSCs in cancer promotion. © 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
authors.affiliation: Oncology and Immunology Section, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
authors.forename: S
authors.identifier: 0000-0003-2544-1673
authors.initials: S
authors.lastname: Solito
authors.affiliation: Oncology and Immunology Section, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Pinton
authors.affiliation: Oncology and Immunology Section, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.|Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Mandruzzato
mesh_terms: D006801:Humans; D007108:Immune Tolerance; D000072737:Myeloid-Derived Suppressor Cells / Q000276:immunology*; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000098:blood supply / Q000276:immunology*; D009389:Neovascularization, Pathologic / Q000276:immunology; D059016:Tumor Microenvironment / Q000276:immunology*
keywords: immune suppression; myeloid-derived suppressor cells; tumour promotion